VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Cassava Sciences (NASDAQ:FLNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Analyst Ratings
This is a breakdown of recent ratings and price targets for VYNE Therapeutics and Cassava Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than VYNE Therapeutics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VYNE Therapeutics | $570,000.00 | 38.54 | -$26.48 million | ($0.38) | -1.73 |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.82 |
VYNE Therapeutics has higher revenue and earnings than Cassava Sciences. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the S&P 500.
Institutional and Insider Ownership
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares VYNE Therapeutics and Cassava Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VYNE Therapeutics | -4,726.21% | -70.42% | -63.46% |
| Cassava Sciences | N/A | -53.90% | -34.20% |
Summary
Cassava Sciences beats VYNE Therapeutics on 8 of the 13 factors compared between the two stocks.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
